A Phase 1/1b, Multicenter, Open-Label Study of Intravenous RXDX-107 in Adult Patients With Locally Advanced or Metastatic Solid Cancer

Trial Profile

A Phase 1/1b, Multicenter, Open-Label Study of Intravenous RXDX-107 in Adult Patients With Locally Advanced or Metastatic Solid Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2016

At a glance

  • Drugs RXDX 107 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Ignyta
  • Most Recent Events

    • 23 Sep 2016 Status changed from active, no longer recruiting to discontinued.
    • 21 Apr 2016 Status changed from recruiting to active, no longer recruiting.
    • 11 Sep 2015 Status changed from planning to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top